Key result
Treatment with recombinant human soluble thrombomodulin did not increase plasma activated protein C activity in septic patients with disseminated intravascular coagulation.
Why the study?
Does recombinant human soluble thrombomodulin increase circulating activated protein C levels in septic patients?
Observational (n=8)
No
Does recombinant human soluble thrombomodulin increase circulating activated protein C levels in septic patients?
Recombinant human soluble thrombomodulin does not increase systemic circulating activated protein C levels in septic patients, suggesting its anticoagulant effects may act locally.
Answers are grounded in this paper and cite their sources.
Questions rhTM mechanism in septic DIC; leaves open net clinical benefit for prospective trials.
BACKGROUND: Recombinant human soluble thrombomodulin (rTM) has been used for the treatment of disseminated intravascular coagulation in Japan, and an international phase III clinical trial for rTM is currently in progress. rTM mainly exerts its anticoagulant effects through an activated protein C (APC)-dependent mechanism, but the circulating APC levels after rTM treatment have not been clarified. This prospective observational study investigated plasma APC levels after rTM treatment. METHODS: Plasma levels of soluble thrombomodulin, thrombin-antithrombin complex (TAT), protein C, and APC were measured in eight septic patients treated with rTM. APC generation in vitro was assessed in the presence or absence of rTM. RESULTS: rTM significantly increased thrombin-mediated APC generation in vitro. In septic patients, soluble thrombomodulin levels were significantly increased during a 30-60-min period of rTM treatment and TAT levels were decreased. However, APC activity was not increased during the treatment period. CONCLUSIONS: Plasma APC activity is not increased in septic patients treated with rTM. It is possible that APC acts locally and does not circulate systemically.
No takes yet. Share an insight, caveat, or question.
Arishima et al. (2018) conducted an observational in Sepsis-associated disseminated intravascular coagulation (DIC) (n=8). Recombinant human soluble thrombomodulin (rTM) vs. Baseline (pre-treatment) was evaluated on Plasma activated protein C (APC) levels. Treatment with recombinant human soluble thrombomodulin did not increase plasma activated protein C activity in septic patients with disseminated intravascular coagulation.
Synapse has enriched 10 related papers. Consider them for comparative context: